Articles de revue sur le cancer de la vessie - Derni ères parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer de la vessie (16 novembre 2007):

Lymphadenectomy in bladder cancer: a review.
Buscarini M, Josephson DY, Stein JP.
Urol Int. 2007;79(3):191-9.

Coffee and cancer risk: an update.
La Vecchia C, Tavani A.
Eur J Cancer Prev. 2007 Oct;16(5):385-9.

Neo-adjuvant and adjuvant chemotherapy in bladder cancer.
D'Auria G, Ciprotti M, Conte D, Iacovelli R, Palazzo A, Pellegrino A,
Cortesi E.
Ann Oncol. 2007 Jun;18 Suppl 6:vi162-3.

Therapy of metastatic bladder carcinoma.
Iaffaioli RV, Milano A, Caponigro F.
Ann Oncol. 2007 Jun;18 Suppl 6:vi153-6.

Treatment of muscle-invasive bladder cancer.
Sherif A, Jonsson MN, Wiklund NP.
Expert Rev Anticancer Ther. 2007 Sep;7(9):1279-83.

Emerging drugs for targeted therapy of bladder cancer.
Agarwal PK, Black PC, McConkey DJ, Dinney CP.
Expert Opin Emerg Drugs. 2007 Sep;12(3):435-48.

Open radical cystectomy with lymphadenectomy remains the treatment of
choice for invasive bladder cancer.
Huang GJ, Stein JP.
Curr Opin Urol. 2007 Sep;17(5):369-75.

New developments in first- and second-line chemotherapy for
transitional cell, squamous cell and adenocarcinoma of the bladder.
De Santis M, Bachner M.
Curr Opin Urol. 2007 Sep;17(5):363-8.

The value of bladder-conserving strategies in muscle-invasive bladder
carcinoma compared with radical surgery.
Merseburger AS, Kuczyk MA.
Curr Opin Urol. 2007 Sep;17(5):358-62.

Current strategies for first and second line intravesical therapy for
nonmuscle invasive bladder cancer.
Hendricksen K, Witjes JA.
Curr Opin Urol. 2007 Sep;17(5):352-7.

Recent developments in fluorescence cystoscopy: do novel agents bring
a benefit?
Schmidbauer J, Marberger M.
Curr Opin Urol. 2007 Sep;17(5):347-51.

Bladder cancer biomarkers: current developments and future
implementation.
Alvarez A, Lokeshwar VB.
Curr Opin Urol. 2007 Sep;17(5):341-6.

Improving the management of bladder cancer with fluorescence
cystoscopy.
Grossman HB.
J Environ Pathol Toxicol Oncol. 2007;26(2):143-7.

Application of artificial intelligence to the management of urological
cancer.
Abbod MF, Catto JW, Linkens DA, Hamdy FC.
J Urol. 2007 Oct;178(4 Pt 1):1150-6.

Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes
and smoking on bladder carcinogenesis: a literature-based systematic
HuGE review and evidence synthesis.
Sanderson S, Salanti G, Higgins J.
Am J Epidemiol. 2007 Oct 1;166(7):741-51.

Management of patients with upper urinary tract transitional cell
carcinoma.
Raman JD, Scherr DS.
Nat Clin Pract Urol. 2007 Aug;4(8):432-43.

Adjuvant radiotherapy in bladder cancer: time to take a fresh look?
Murthy V, Zaghloul MS.
Urol Oncol. 2007 Jul-Aug;25(4):353-4.

Difficult decisions in urologic oncology: management of high-grade T1
transitional cell carcinoma of the bladder.
Soloway MS, Lee CT, Steinberg GD, Ghandi AA, Jewett MA.
Urol Oncol. 2007 Jul-Aug;25(4):338-40.

Databases and the future of clinical trials in bladder cancer.
Adams RM.
Urol Oncol. 2007 Jul-Aug;25(4):330-2.

Clinical and therapeutic significance of aberrant differentiation
patterns in bladder cancer.
Black PC, Brown GA, Dinney CP.
Expert Rev Anticancer Ther. 2007 Jul;7(7):1015-26.



(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)